9Nomura S, Nakamura T, Tschoepe D. Cytomcric analysis of high shearinduced platelet micropaticles and effect of cytokines on microparticle gengeration. Cytometry, 2000,40:173-181.
10Hagberg IA, Lyberg T. Blood platelet activation cvaluation by flow cytomery: optimized methods for clinical studies. Platelet,2000,11 : 137-150.
4[1]Fukutake K. In vitro observations on antithrombotic action of urinastatin[J].Nippon Yakurigaku Zasshi, 1987,90(3):163-169.
5[2]Mimura K, Shinozawa K, Kobayashi T, et al.Inhibitory effect of ulinastatin on the alpha-thrombin activation of factors V and VIII[J]. Rinsho Byori, 1992 ,40(3): 317-320.
6[3]Lin SD,Endo R,Sato A,et al. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis.J Gastroenterol[J]. Hepatology,2002,17(2):140-147.
7[4]Law NL, Ng KF, Irwin MG, et al.Comparison of coagulation and blood loss during anaesthesia with inhaled isoflurane or intravenous propofol[J].Br J Anaesth,2001,86(1):94-98.
8[5]Aoki H, Mizobe T, Nozuchi S,et al. In vivo and in vitro studies of the inhibitory effect of propofol on human platelet aggregation[J].Anesthesiology, 1998 ,88(2): 362-370.
9[6]Nii A, Morishita H, Yamakawa T, et al. Design of variants of the second domain of urinary trypsin inhibitor (R-020) with increased factor Xa inhibitory activity[J].J Biochem, 1994 ,115(6):1107-1112.
10[7]Morishita H, Yamakawa T, Matsusue T, et al. Novel factor Xa and plasma kallikrein inhibitory-activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor[J].Thromb Res, 1994,73(3-4):193-204.
2Connolly GC,Khorana AA.Risk stratification for cancer-associated venous thromboembolism.Best Pract Res Clin Haematol,2009,22(l):35-47.
3Blom JW,Doggen CJ,Osanto S,et al.Malignancies,prothrombotic mutations,and the risk of venous thrombosis.JAMA,2005,293(6):715-22.
4Chew HK,Wun T,Harvey D,et al.Incidence of venous thromboembolism and its effect on survival among patients with common cancers.Arch Intern Med,2006,166(4):458-64.
5Kessler CM.The link between cancer and venous thromboembolism:a review.Am J Clin Oncl,2009,32(4 Suppl):S3-7.
6Agnelli G,Bolis G,Capussotti L,et al.A clinical outcome-based prospective study on venous thromboembolism after cancer surgery:the@ RISTOS project.Ann Surg,2006,243(1):89-95.
7Sousou T,Khorana AA.New insights into cancer-associated thrombosis.Arterioscler Thromb Vase Biol,2009,29(3):316-320.
8Connolly GC,Khorana AA.Risk stratification for cancer-associated venous thromboembolism.Best Pract Res Clin Haematol,2009.22(1):35-47.
9WunT,White RH.Venous thromboembolism (VTE) in patients with cancer:epidemiology and risk factors.Cancer Invest,2009,27 Suppl 1-63-74.
10Negus JJ,Gardner JJ,Tann O,et al.Thromboprophylaxis in major abdominal surgery for cancer.Eur J Surg Oncol,2006,32(9):911-916.
